Sera Prognostics, Inc. Class A (SERA)

Over the past six months, Sera Prognostics' stock experienced several notable events. The company announced its Q3 2025 earnings on November 13, 2025. In January 2026, a landmark study on the PreTRM® Test and targeted interventions was published. On March 18, 2026, the company reported its Q4 and full year 2025 financial results, indicating a 58% year-over-year plummet in fourth-quarter revenue, while also outlining plans for 2026 expansion and stating that its cash is expected to fund operations through key commercial milestones into 2028. As of April 9, 2026, the stock price had decreased by 31.70% over the past six months. In the past three months, Sera Prognostics insiders have sold more of the company's stock than they have bought, however, in March 2026, analysts upgraded Sera Prognostics to a "Buy" rating and issued positive ratings.

Based on the available information, there is no explicit mention or indication of significant demand seasonality for Sera Prognostics, Inc.'s products and services. The nature of its primary product, the PreTRM test, which addresses a continuous need in pregnancy care, suggests that demand may not be subject to strong seasonal fluctuations.

Sera Prognostics operates in the Healthcare sector, focusing on Medical Devices and Biotechnology, specifically Diagnostic Equipment and FemTech. The company discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services. Its major product is the PreTRM® test, a non-invasive blood test administered to pregnant women to predict their risk of spontaneous premature delivery. The company is also developing a pipeline of other novel blood-based biomarker tests and predictive analytic products for various pregnancy-related conditions.

Sera Prognostics is headquartered in Salt Lake City, Utah, United States. Its current sales are primarily within the United States. The company is actively expanding its commercial discussions with payers across 13 U.S. states and aims to expand its partner programs to 15–17 states by the end of 2026. The company also has plans for potential international expansion, including into Europe, and is preparing for European CE marking.

Sera Prognostics has cultivated a reputation as "The Pregnancy Company," emphasizing its dedication to improving maternal and neonatal health. A large study found that the company's maternal biomarker test reduces neonatal morbidities and improves outcomes. The publication of the pivotal PRIME Study in January 2026, demonstrated that the PreTRM test reduced early preterm births and neonatal complications. The company presented at the 43rd Annual J.P. Morgan Healthcare Conference in January 2025. In March 2026, analysts issued positive ratings and upgraded the stock to a "Buy". The company's plans to expand partner programs across U.S. states and explore international expansion also contribute to a perception of growth and impact.

Sera Prognostics has a mixed ownership structure, including institutional, retail, and individual investors. Approximately 33.31% to 54.64% of the company's stock is held by institutional investors. Insiders hold between 7.87% and 13.50% of the stock. Public companies and individual investors own approximately 55.43% of the stock.